Quantum Biopharma Ltd.
QNTMDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
20dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
Firibastat
Hypertension
QGC001
Essential Hypertension
Ramipril
Myocardial Infarction
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Firibastat | Phase 3 | Hypertension | - | - |
QGC001 | Phase 2 | Essential Hypertension | - | - |
Ramipril | Phase 2 | Myocardial Infarction | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Quantum Biopharma Ltd.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Quantum Biopharma Ltd.'s (QNTM) pipeline across Phase 3, Phase 2. Its lead program is Firibastat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Quantum Biopharma Ltd.'s next FDA catalyst?→
Quantum Biopharma Ltd.'s (QNTM) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track QNTM biotech catalysts?→
Add QNTM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Quantum Biopharma Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.